How should I taper off Risperdal (risperidone)?

Oral solution (1 mg/mL) supports precise sub-tablet dosing. Discontinuation carries risk of dopamine supersensitivity psychosis, particularly after prolonged D2 blockade. Hyperprolactinemia (highest among atypicals) typically resolves with reductions. Use oral solution (1 mg/mL) for proportional reductions below 0.5 mg. Extremely gradual hyperbolic taper is essential after long-term use given supersensitivity risk; monitor for emergent EPS, akathisia, and psychotic relapse.

Risperdal Tapering Guide

Q: What are the withdrawal symptoms of Risperdal (risperidone)?

Common withdrawal symptoms of Risperdal (risperidone) include: insomnia, nausea, anxiety, psychosis risk, movement disorders. Symptom severity varies by individual, dose, and duration of use.

risperidone

Atypical AntipsychoticFDA 1993

Try TaperMeds

Boxed Warning

Increased mortality in elderly patients with dementia-related psychosis.

Overview

Risperidone is an atypical antipsychotic approved for schizophrenia, bipolar mania, and irritability associated with autistic disorder. It has high affinity for dopamine D2 and serotonin 5-HT2A receptors and carries a notable risk of hyperprolactinemia.

Common Doses

0.5mg, 1mg, 2mg, 3mg, 4mg

Formulations

Tablets: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Orally disintegrating tablets (M-Tab): 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Oral solution: 1mg/mL; Long-acting injection (Risperdal Consta): 12.5mg, 25mg, 37.5mg, 50mg

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. Also antagonizes alpha-1, alpha-2 adrenergic, and histamine H1 receptors. Higher D2 affinity than most atypicals contributes to EPS risk at higher doses and hyperprolactinemia.

Taper Notes

Oral solution (1 mg/mL) supports precise sub-tablet dosing. Discontinuation carries risk of dopamine supersensitivity psychosis, particularly after prolonged D2 blockade. Hyperprolactinemia (highest among atypicals) typically resolves with reductions.

Maudsley Deprescribing Guidance

Use oral solution (1 mg/mL) for proportional reductions below 0.5 mg. Extremely gradual hyperbolic taper is essential after long-term use given supersensitivity risk; monitor for emergent EPS, akathisia, and psychotic relapse.

Common Withdrawal Symptoms

insomnianauseaanxietypsychosis riskmovement disorders

Interactions & Safety

Drug Interactions

CYP2D6 inhibitors (fluoxetine, paroxetine) increase risperidone levels
CYP3A4 inducers (carbamazepine, phenytoin, rifampin) decrease risperidone levels
CYP3A4 inhibitors (ketoconazole, itraconazole) increase risperidone levels

Food Interactions

Food does not significantly affect absorption
Avoid alcohol (additive CNS depression)

Contraindications

Known hypersensitivity to risperidone or paliperidone

Toxicity

Hyperprolactinemia (highest among atypicals). Extrapyramidal symptoms at higher doses. Metabolic effects (weight gain, hyperglycemia, dyslipidemia). Orthostatic hypotension. Tardive dyskinesia. NMS rarely.

Pharmacokinetics

ADME Profile

Absorption

Well absorbed after oral administration. Bioavailability ~70% (oral solution) to ~66% (tablets). Tmax ~1 hour. Food does not significantly affect absorption.

Distribution

~1–2 L/kg

Metabolism

Hepatic via CYP2D6 (primary) to the active metabolite 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. CYP3A4 is a minor pathway.

Elimination

Renal (~70%) and fecal (~14%). In extensive CYP2D6 metabolizers, active moiety (risperidone + 9-OH-risperidone) half-life is ~20 hours.

Protein Binding

~90% (risperidone), ~77% (9-hydroxyrisperidone)

Clearance

~5–8 mL/min/kg (total active moiety clearance)

Build Risperdal taper plans in minutes

TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.